Business · 22/06/2004Updated: 10/17/2026 · 1 min read
FDA Releases Guidances for Medical Imaging Drug and Biological Products Developers
Summary
The Food and Drug Administration (FDA) has made available three guidances to help medical imaging drug and biological product developers plan and coordinate clinical trials and prepare regulatory submissions, including INDs, NDAs, BLAs, ANDAs, and NDA/BLA supplements.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →